SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

FDA Rejects Summit Therapeutics’ Ivonescimab Application for Lung Cancer Treatment

Summit Therapeutics said the FDA rejected its application for ivonescimab as a lung cancer treatment. Shares fell pre-bell.

SMMT

Related stories